{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of NRAS, KRAS and BRAF from peripheral blood samples.","groups":[{"description":"Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of KRAS from peripheral blood samples.","id":"OG000","title":"Detection of KRAS Mutations Using cfDNA"},{"description":"Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of NRAS from peripheral blood samples.","id":"OG001","title":"Detection of NRAS Mutations Using cfDNA"},{"description":"Ultra-deep sequencing will be performed on cfDNA to assess the feasibility of detecting mutations of BRAF from peripheral blood samples.","id":"OG002","title":"Detection of BRAF Mutations Using cfDNA"}],"paramType":"NUMBER","populationDescription":"64 cfDNA specimens from 53 Myeloma patients including 13 patients from this trial that were included in this analysis","reportingStatus":"POSTED","timeFrame":"Baseline and every even cycle and at progression, an average of 9 cycles (9 months)","title":"Detection of RAS and RAF Mutations Using cfDNA","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"MUTATIONS"}